The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.

Session: Poster and Exhibition Hall Reception Poster Title:PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS ...

About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic ...

For more information about Webull, visit www.webull.com. Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with ...

Palisade Bio, Inc. announced positive preliminary findings from its ongoing Phase 1a/b clinical study of PALI-2108, a treatment for Ulcerative Colitis (UC), indicating high tolerability and safety ...

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.

Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,”“Palisade Bio” or the“Company”), a clinical-stage ...